COAPT-Like Profile Predicts Long-Term Outcomes in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation.

[1]  C. Metze,et al.  Impact of COAPT trial exclusion criteria in real-world patients undergoing transcatheter mitral valve repair. , 2020, International journal of cardiology.

[2]  M. Metra,et al.  Impact of disproportionate secondary mitral regurgitation in patients undergoing edge-to-edge percutaneous mitral valve repair. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[3]  M. Mack,et al.  Echocardiographic Outcomes After Transcatheter Leaflet Approximation in Patients With Secondary Mitral Regurgitation , 2019 .

[4]  I. Palacios,et al.  Association of Pulmonary Hypertension With Clinical Outcomes of Transcatheter Mitral Valve Repair. , 2019, JAMA cardiology.

[5]  A. Íñiguez,et al.  The European Registry of MitraClip in Acute Mitral Regurgitation following an acute myocardial infarction (EREMMI). , 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[6]  D. Maucort-Boulch,et al.  Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years , 2019, European journal of heart failure.

[7]  B. Prendergast,et al.  Mitral regurgitation in heart failure: time for a rethink. , 2019, European heart journal.

[8]  D. Capodanno,et al.  Five-year clinical outcomes after percutaneous edge-to-edge mitral valve repair: Insights from the multicenter GRASP-IT registry. , 2019, American heart journal.

[9]  O. Alfieri,et al.  Treatment of functional mitral regurgitation in chronic heart failure: can we get a ‘proof of concept’ from the MITRA‐FR and COAPT trials? , 2019, European journal of heart failure.

[10]  A. Sannino,et al.  Proportionate and Disproportionate Functional Mitral Regurgitation: A New Conceptual Framework That Reconciles the Results of the MITRA-FR and COAPT Trials. , 2019, JACC. Cardiovascular imaging.

[11]  M. Metra,et al.  Left ventricular reverse remodelling predicts long‐term outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry , 2018, European journal of heart failure.

[12]  O. Alfieri,et al.  Mid‐term outcomes (up to 5 years) of percutaneous edge‐to‐edge mitral repair in the real‐world according to regurgitation mechanism: A single‐center experience , 2018, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[13]  M. Mack,et al.  Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial , 2018, American heart journal.

[14]  M. Mack,et al.  Transcatheter Mitral‐Valve Repair in Patients with Heart Failure , 2018, The New England journal of medicine.

[15]  D. Maucort-Boulch,et al.  Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation , 2018, The New England journal of medicine.

[16]  J. Mascherbauer,et al.  Refining the prognostic impact of functional mitral regurgitation in chronic heart failure , 2017, European heart journal.

[17]  Jeroen J. Bax,et al.  2017 ESC/EACTS Guidelines for the management of valvular heart disease. , 2017, European heart journal.

[18]  L. Fleisher,et al.  2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.

[19]  M. Metra,et al.  Percutaneous edge-to-edge mitral valve repair for the treatment of acute mitral regurgitation complicating myocardial infarction: A single centre experience. , 2017, International journal of cardiology.

[20]  H. Schunkert,et al.  Predictors for long‐term survival after transcatheter edge‐to‐edge mitral valve repair , 2017, Journal of interventional cardiology.

[21]  M. Neuss,et al.  Role of Right Ventricular Dysfunction and Diabetes Mellitus in N-terminal pro-B-type Natriuretic Peptide Response of Patients With Severe Mitral Regurgitation and Heart Failure After MitraClip. , 2017, International heart journal.

[22]  C. Rapezzi,et al.  Percutaneous mitral valve repair: The last chance for symptoms improvement in advanced refractory chronic heart failure? , 2017, International journal of cardiology.

[23]  A. Colombo,et al.  Right ventricular evaluation to improve survival outcome in patients with severe functional mitral regurgitation and advanced heart failure undergoing MitraClip therapy. , 2016, International journal of cardiology.

[24]  P. Boekstegers,et al.  Predictors for short-term outcomes of patients undergoing transcatheter mitral valve interventions: analysis of 778 prospective patients from the German TRAMI registry focusing on baseline renal function. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[25]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[26]  P. Boekstegers,et al.  One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry , 2015, European heart journal.

[27]  G. Filippatos,et al.  Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 2: Endpoint Definitions: A Consensus Document From the Mitral Valve Academic Research Consortium. , 2015, Journal of the American College of Cardiology.

[28]  D. Capodanno,et al.  Predictors of clinical outcomes after edge-to-edge percutaneous mitral valve repair. , 2015, American heart journal.

[29]  J. Tijssen,et al.  Predictors of outcome in patients undergoing MitraClip implantation: An aid to improve patient selection. , 2015, International journal of cardiology.

[30]  M. Metra,et al.  Effectiveness of MitraClip therapy in patients with refractory heart failure. , 2015, Journal of interventional cardiology.

[31]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[32]  D. Capodanno,et al.  Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System: 30-day and 12-month follow-up from the GRASP Registry. , 2014, European heart journal cardiovascular Imaging.

[33]  S. Blankenberg,et al.  Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry. , 2014, Journal of the American College of Cardiology.

[34]  J. Hausleiter,et al.  Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. , 2013, Journal of the American College of Cardiology.

[35]  M. Neuss,et al.  Patient selection criteria and midterm clinical outcome for MitraClip therapy in patients with severe mitral regurgitation and severe congestive heart failure , 2013, European journal of heart failure.

[36]  A. Branzi,et al.  Prognostic implications of functional mitral regurgitation according to the severity of the underlying chronic heart failure: a long‐term outcome study , 2010, European journal of heart failure.